Hereditary Oncology Testing: Wei Shen, Ph.D.
Wei Shen, Ph.D., discusses Mayo Clinic Laboratories’ new hereditary oncology panels, which use next-generation sequencing to identify germline alterations associated with increased cancer risk. Curated through a rigorous selection framework developed by M
Episode 108 of the Answers from the Lab podcast, hosted by Mayo Clinic Laboratories, titled "Hereditary Oncology Testing: Wei Shen, Ph.D." was published on November 16, 2021 and runs 10 minutes.
November 16, 2021 ·10m · Answers from the Lab
Summary
Wei Shen, Ph.D., discusses Mayo Clinic Laboratories’ new hereditary oncology panels, which use next-generation sequencing to identify germline alterations associated with increased cancer risk. Curated through a rigorous selection framework developed by Mayo Clinic oncology experts, the panels include only clinically significant genes to provide clarity on diagnosis, prognosis, and treatment approaches for individuals at risk for hereditary cancers.
Episode Description
(00:32):
But before we get started, Dr. Shen, could you provide us with a little bit about you and your background?
(01:15):
So why don't we start our discussion today with having you give us a brief overview of these new hereditary oncology panels.
(03:56):
Can you tell us which patients should have this type of testing and when it should be performed?
(05:31):
Do you want to talk about what other test options are available and how our testing is different or how it compares to this other testing?
(06:51):
So then the last question I have for you today, and maybe the most important is how are these results used in patient care?
Similar Episodes
Apr 5, 2026 ·6m
Apr 4, 2026 ·59m
Apr 2, 2026 ·5m
Mar 29, 2026 ·7m
Mar 21, 2026 ·59m
Mar 19, 2026 ·5m